Gabrielle Sulzberger - 24 Jun 2021 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role: Director
Signature: /s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 24 Jun 2021
Net transactions value: $0
Form type: 4
Filing time: 24 Jun 2021, 17:32:43 UTC
Previous filing: 24 Jun 2021
Next filing: 04 Oct 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CERE	Common Stock	Options Exercise		+14,270	+40%		49,624	24 Jun 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CERE	Restricted Stock Units	Options Exercise	$0	-14,270	-50%	$0.000000	14,270	24 Jun 2021	Common Stock	14,270		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock.
F2	14,270 RSUs vested on June 24, 2021, the second anniversary of the vesting commencement date of June 24, 2019 (the "Vesting Commencement Date"), with the remainder vesting on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service relationship with the Issuer through each such date.